I find it highly odd that we have multiple companies suddenly chasing the same therapy with very similar methods.I think FX-322 and REGAIN stand a chance to enter the market in or before 2025, but that will depend of course on how well they perform in the trials. I don't think either of those will provide the cure. Change will be incremental, with each new generation of drugs and combinations of those drugs providing better results. And that also depends on how badly the condition of a patient is. But it is obvious things are moving in the right direction. There's never been a time where multiple drugs to restore hearing are in clinical trials. Not to mention drugs that will probably enter trials within the next 5 years, like Otonomy's and Decibel's hair cell loss drugs and Rinri's stem cell therapy.
I actually believe something is happening behind the scenes in the science community to spark this.
There's no way 3 or more companies discovered the same thing at the same time.
Some new diagnostic, or small molecule development happened for the community and pushed everyone onto the same path.
This is just my hunch of course. But yeah, it's very odd, in a good way.